Resistance to Complement Activation, Cell Membrane Hypersialylation and Relapses in Chronic Lymphocytic Leukemia Patients Treated With Rituximab and Chemotherapy
Oncotarget - United States
doi 10.18632/oncotarget.25657
Full Text
Open PDFAbstract
Available in full text
Categories
Date
June 12, 2018
Authors
Publisher
Impact Journals, LLC